Navigation Links
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer

ht; position: relative;">

"AV-412 showed potent inhibition of the EGFR L858R mutations and, in two well-established animal models, demonstrated dose-dependant tumor regression in both small and large lung tumors and complete regression of lung tumors at a dose where erlotinib is inactive," said Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals. "These data, while early, highlight the promise of AV-412 as an option for lung cancer patients who carry the EGFR L858R mutation, as well as patients who become resistant to first-generation tyrosine kinase inhibitors. We are looking forward to initiating Phase 2 trials as soon as we establish an appropriate dose in the current Phase 1 study, which was initiated last October."

To provide robust models for translational research supporting the development of novel agents for lung cancer, AVEO generated a series of inducible mouse lung cancer models using AVEO's Human Response Prediction(TM) Platform. Using this proprietary platform, AVEO generated several different models covering the most prevalent oncogenic mutations including EGFR(L858R), EGFR(L858R/T790M) and KRAS(G12V). Unlike studies in primary genetically engineered tumor models, this approach enables the quantitative and comparative analysis of different drugs, doses, schedules and combinations to optimize drug selection and clinical trial design in the clinic.

Utilizing these novel models, AVEO evaluated the activity of AV-412 in non-small cell lung cancer tumors. Data presented today at the AACR meeting show that AV-412 is highly active against tumors from the chimeric model carrying the EGFRL858R mutation, exhibiting an ED50 of 0.1 mg/kg as a daily dose. AV-412 is greater than 10 times more potent than erlotinib in this model, one mg/kg PO AV-412 resulted in complete tumor regression, whereas erlotinib is active at 10mg/kg, but inactive at 1mg/kg. More importantly, AV-412 was found to be active against tumors from chimeric lung adenocar
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:2/27/2015)... CHAPEL HILL, N.C. , Feb. 27, 2015 /PRNewswire/ ... evolved over the past decade but one thing hasn,t ... for MSLs to build relationships with Key Opinion Leaders. ... are recognized as the most valuable type of interaction, ... external limits on their KOL interactions. This is just ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... a pre-clinical study published in the Proceedings ... www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ® ... checkpoint inhibitor), suppression of tumor growth was enhanced ... treating certain hematologic cancers and solid tumors with ...
(Date:2/27/2015)... - La ... monitoraggio dell,infarto congestizio (CHF - Congestive Heart Failure) ...   Vectorious Medical Technologies, società ... il monitoraggio cardiaco destinato a pazienti affetti da ... concluso una raccolta di finanziamenti per 5 milioni ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... 2011 Verilogue, the physician-patient dialogue expert, today ... initiatives, including CareCoach.com, the company,s unique service that ... caregivers and their physicians. The company will be ... e-Patient Connections; the Hyatt at Bellevue; ...
... YORK, Sept. 20, 2011 Reportlinker.com announces ... available in its catalogue: ... Outlook to 2017 ... Africa Cardiovascular Devices Market Outlook to 2017 ...
Cached Medicine Technology:Verilogue to Present at Upcoming Health IT and Patient-Focused Conferences 2Middle East and Africa Cardiovascular Devices Market Outlook to 2017 2Middle East and Africa Cardiovascular Devices Market Outlook to 2017 3Middle East and Africa Cardiovascular Devices Market Outlook to 2017 4Middle East and Africa Cardiovascular Devices Market Outlook to 2017 5Middle East and Africa Cardiovascular Devices Market Outlook to 2017 6Middle East and Africa Cardiovascular Devices Market Outlook to 2017 7Middle East and Africa Cardiovascular Devices Market Outlook to 2017 8Middle East and Africa Cardiovascular Devices Market Outlook to 2017 9Middle East and Africa Cardiovascular Devices Market Outlook to 2017 10Middle East and Africa Cardiovascular Devices Market Outlook to 2017 11Middle East and Africa Cardiovascular Devices Market Outlook to 2017 12Middle East and Africa Cardiovascular Devices Market Outlook to 2017 13Middle East and Africa Cardiovascular Devices Market Outlook to 2017 14Middle East and Africa Cardiovascular Devices Market Outlook to 2017 15Middle East and Africa Cardiovascular Devices Market Outlook to 2017 16Middle East and Africa Cardiovascular Devices Market Outlook to 2017 17
(Date:2/28/2015)... NY (PRWEB) February 28, 2015 A ... federal testosterone lawsuits that have been filed by law ... the second week in March, the Firm notes. ... website, parties involved in the federal litigation will meet ... matters related to prescription therapy treatments designed to raise ...
(Date:2/28/2015)... New York, NY (PRWEB) February 28, 2015 ... DIY Phishing Kits Make It Easy For Scammers To Steal ... about anyone can get their hands on a DIY phishing ... But it also touched on another important point about ... ways these kits are often implemented, “like compromising legitimate content ...
(Date:2/28/2015)... Aliso Viejo, California (PRWEB) February 28, 2015 ... announced the release of a new overlay plugin for Final ... Pixel Film Studios. , “FCPX Overlay Chromatic gives users total ... X,” said Christina Austin, CEO of Pixel Film Studios. “FCPX ... while maintaining an easy to use interface.” , FCPX Overlay ...
(Date:2/28/2015)... February 28, 2015 Plugin creators from ... Volume 2. A fully customizable transition pack ... Volume 2 gives users total control over 30 transition ... CEO of Pixel Film Studios. “TransFold Volume 2 gives ... , TransFold Volume 2 from Pixel Film Studios brings ...
(Date:2/28/2015)... Vegas, NV (PRWEB) February 28, 2015 My ... will be sending a team to Las Vegas, Nevada for ... Market Week is one of the leading consumer-goods tradeshows and ... vendors at this year’s event. My Shiney Hiney can be ... a fresh, modern design for the at-home personal hygiene brush ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2
... Consumers Urged To Use Online Quality Information Before Choosing a ... ... Leapfrog Group and the Buyers,Health Care Action Group (BHCAG) today released this ... 1,200,hospitals. Methodist Hospital in St. Louis Park, St. Mary,s Hospital in,Rochester and ...
... Angeles,Area Chamber of Commerce today endorsed Governor Schwarzenegger,s ... payroll fee on employers,with 10 or more employees ... much,to providing health insurance for their employees. The ... and other State,Legislators to use the Governor,s proposal ...
... CHICAGO, Sept. 17 Brookdale Senior Living,Inc. (NYSE: ... has declared a,quarterly cash dividend on its common stock ... 2007. The $0.50 per share dividend is payable,on October ... stock on,September 28, 2007. Brookdale Senior Living Inc. ...
... Takes $1 Million From Insurance Cos, Plans to Force ... Sept. 17 The following,media advisory was issued today ... When: 17th September 2007, 1:30 PM Pacific Standard Time ... Where: Satellite: Galaxy 26 C Band analog @ ...
... 2007 -- A new study by researchers at the University ... for you. , Researchers found that a storyline on ... obesity, hypertension and healthy eating habits had a positive impact ... , The study, published in the Sept. 14 Journal of ...
... public,service announcement is being issued by FMQAI: Helping ... time.,You could be that person. The Every Diabetic Counts ... Health Workers and,conduct a diabetes education program. Call ... place in this free, two and a half-day workshop. ...
Cached Medicine News:Health News:Four Minnesota Hospitals Rate High For Patient Safety and Quality 2Health News:Los Angeles Area Chamber of Commerce Endorses Governor Schwarzenegger's Health Care Proposal 2Health News:ER episode impacts viewers' health knowledge and behavior 2
The ultimate ultrasound system for clinical ophthalmologists....
PremierEdge Stab Knives - 30....
... Technology for the total eye. Whether ... scanning mode or set independently to ... multi-frequency settings are adjustable to accommodate ... transducer for use with tonometer-mounted, hand-held ...
PremierEdge™ MVR Knives. Angled....
Medicine Products: